Skip to main content

Rabies

12
Pipeline Programs
12
Companies
21
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
0
2
1
6
2
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Vaccine
1393%
RNA Therapeutic
17%
+ 12 programs with unclassified modality

Competitive Landscape

12 companies ranked by most advanced pipeline stage

Sandoz
SandozAustria - Kundl
5 programs
1
3
1
Purified Chick Embryo Cell Inactivated Rabies VaccinePhase 4Vaccine1 trial
Abbreviated Zagreb 2-1-1 schedulePhase 31 trial
RabiesPhase 31 trial
ZagrebPhase 31 trial
Three 1 mL doses of Rabies vaccine and two JE vaccinePhase 2Vaccine1 trial
Active Trials
NCT00694460Completed200Est. Sep 2004
NCT00825305Completed825Est. Jan 2009
NCT01662440Completed661Est. Oct 2013
+2 more trials
Vabiotech
VabiotechVietnam - Hanoi
1 program
1
RABIVAX-SPhase 41 trial
Active Trials
NCT05937113Completed220Est. Oct 2020
Biocorp
BiocorpFrance - Issoire
2 programs
1
1
Rabies Vaccine（Human Diploid Cell）for Human Use,Freeze-driedPhase 3Vaccine1 trial
Rabies Vaccine（Human Diploid Cell）for Human Use,Freeze-driedPhase 1Vaccine1 trial
Active Trials
NCT06132789Completed80Est. Aug 2024
NCT07275645Active Not Recruiting3,000Est. Apr 2027
Sinovac Biotech
Sinovac BiotechChina - Beijing
2 programs
1
1
Rabies VaccinePhase 3Vaccine1 trial
Rabies VaccinePhase 2Vaccine1 trial
Active Trials
NCT07055880Not Yet Recruiting120Est. Jan 2026
NCT07055295Not Yet Recruiting390Est. Dec 2026
Kamada
KamadaIsrael - Negev
2 programs
1
1
KamRAB - HRIGPhase 31 trial
Active rabies vaccinePhase 2/3Vaccine1 trial
Active Trials
NCT02040090Completed118Est. Aug 2014
NCT02912845Completed30Est. Nov 2019
Novartis
NovartisBASEL, Switzerland
4 programs
Three 1 mL doses of Rabies vaccine and two JE vaccinePHASE_2Vaccine
Abbreviated Zagreb 2-1-1 schedulePHASE_3
ZagrebPHASE_3
Purified Chick Embryo Cell Inactivated Rabies VaccinePHASE_4Vaccine
Grifols
GrifolsNEW YORK, NY
3 programs
Human rabies immune globulin 300 IU/mLN/A1 trial
Rabies PEP quality improvement bundleN/A1 trial
RIG-CPHASE_11 trial
Active Trials
NCT05382650Terminated35Est. Oct 2025
NCT04213950Completed70Est. Dec 2020
NCT02139657Completed12Est. May 2014
CureVac
CureVacGermany - Tübingen
3 programs
CV7201 mRNAPHASE_1RNA Therapeutic1 trial
CV8102PHASE_11 trial
Rabipur®PHASE_11 trial
Active Trials
NCT02241135Completed101Est. Feb 2018
NCT02238756Completed72Est. Nov 2016
NCT03713086Completed53Est. Nov 2021
Bharat Biotech
Bharat BiotechIndia - Hyderabad
1 program
Human rabies vaccineN/AVaccine1 trial
Active Trials
NCT02729168Completed120Est. Dec 2015
CSL Seqirus
CSL SeqirusUK - Maidenhead
1 program
Rabies VaccineN/AVaccine
CSL Behring
CSL BehringIL - Bradley
1 program
Rabies VaccineN/AVaccine1 trial
Active Trials
NCT01063140Completed491Est. May 2010
Sanofi
SanofiPARIS, France
1 program
Purified Verocell Rabies VaccinePHASE_4Vaccine1 trial
Active Trials
NCT00260351Completed405Est. Oct 2008

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
VabiotechRABIVAX-S
SandozPurified Chick Embryo Cell Inactivated Rabies Vaccine
SanofiPurified Verocell Rabies Vaccine
Sinovac BiotechRabies Vaccine
BiocorpRabies Vaccine（Human Diploid Cell）for Human Use,Freeze-dried
KamadaKamRAB - HRIG
SandozZagreb
SandozRabies
SandozAbbreviated Zagreb 2-1-1 schedule
KamadaActive rabies vaccine
Sinovac BiotechRabies Vaccine
SandozThree 1 mL doses of Rabies vaccine and two JE vaccine
BiocorpRabies Vaccine（Human Diploid Cell）for Human Use,Freeze-dried
CureVacRabipur®
CureVacCV8102

Showing 15 of 21 trials with date data

Clinical Trials (21)

Total enrollment: 7,897 patients across 21 trials

NCT05937113VabiotechRABIVAX-S

Safety and Immunogenicity of the Inactivated Rabies Vaccine RABIVAX-S Administered Intramuscularly and Intradermally

Start: Jun 2020Est. completion: Oct 2020220 patients
Phase 4Completed
NCT01365494SandozPurified Chick Embryo Cell Inactivated Rabies Vaccine

Immunogenicity and Safety of Rabies Vaccine, Administered With Two Different Simulated Post Exposure Schedules

Start: Jul 2011Est. completion: Nov 2011250 patients
Phase 4Completed
NCT00260351SanofiPurified Verocell Rabies Vaccine

Immunogenicity and Safety of Verorab™ in Indian Population

Start: Dec 2004Est. completion: Oct 2008405 patients
Phase 4Completed
NCT07055295Sinovac BiotechRabies Vaccine

Immunogenicity and Safety of Rabies Vaccine (Serum-free Vero Cell) in a Pre-exposure Prophylaxis Regimen

Start: Mar 2026Est. completion: Dec 2026390 patients
Phase 3Not Yet Recruiting
NCT07275645BiocorpRabies Vaccine（Human Diploid Cell）for Human Use,Freeze-dried

A Clinical Trial of Rabies Vaccine（Human Diploid Cell）for Human Use,Freeze-dried in a Population Aged 10 to 60 Years

Start: Feb 2026Est. completion: Apr 20273,000 patients
Phase 3Active Not Recruiting
NCT02912845KamadaKamRAB - HRIG

Post-marketing Study of KamRAB Administered as a Single Dose With Active Rabies Vaccine in Children Exposed to Rabies

Start: Aug 2016Est. completion: Nov 201930 patients
Phase 3Completed
NCT01680016SandozZagreb

A Randomized, Open-label Study Comparing Two Different Rabies Vaccine Schedules in Chinese Children and Older Adults

Start: Sep 2012Est. completion: Jan 2013644 patients
Phase 3Completed
NCT01662440SandozRabies

Safety and Immunogenicity of 2 Different Vaccination Schedules of Rabies and Japanese Encephalitis Vaccines in Healthy Adult Subjects

Start: Aug 2012Est. completion: Oct 2013661 patients
Phase 3Completed
NCT00825305SandozAbbreviated Zagreb 2-1-1 schedule

Safety and Immunogenicity (Non-inferiority) of a Purified Chick Embryo Cell Vaccine Vaccine Administered in Two Different Schedules (Conventional Versus Abbreviated Schedule)

Start: Nov 2008Est. completion: Jan 2009825 patients
Phase 3Completed
NCT02040090KamadaActive rabies vaccine

Phase II/III Study of the Safety and Effectiveness of HRIG With Active Rabies Vaccine in Healthy Subjects

Start: Apr 2013Est. completion: Aug 2014118 patients
Phase 2/3Completed
NCT07055880Sinovac BiotechRabies Vaccine

Immunogenicity and Safety of Different Dosages of Rabies Vaccine (Serum-free Vero Cell)

Start: Jul 2025Est. completion: Jan 2026120 patients
Phase 2Not Yet Recruiting
NCT00694460SandozThree 1 mL doses of Rabies vaccine and two JE vaccine

Evalution of Immunogenicity, Safety and Booster Response of a Rabies Vaccine Administered Concomitantly With Japanese Encephalitis Vaccine in Toddlers

Start: Aug 2002Est. completion: Sep 2004200 patients
Phase 2Completed
NCT06132789BiocorpRabies Vaccine（Human Diploid Cell）for Human Use,Freeze-dried

A Clinical Trial of Rabies Vaccine（Human Diploid Cell）for Human Use,Freeze-dried in a Population Aged 10-60 Years

Start: Nov 2023Est. completion: Aug 202480 patients
Phase 1Completed
NCT03713086CureVacRabipur®

A Study to Assess the Safety, Reactogenicity and Immune Response of CureVac's Candidate Rabies mRNA Vaccine in Healthy Adults

Start: Oct 2018Est. completion: Nov 202153 patients
Phase 1Completed
NCT02238756CureVacCV8102

Safety and Tolerability of CV8102 Alone and in Combination With a Rabies Virus Vaccine in Healthy Adults

Start: Sep 2014Est. completion: Nov 201672 patients
Phase 1Completed
NCT02139657GrifolsRIG-C

An Open-label, Single-Arm Study to Evaluate the Safety and Rabies Virus Antibody Titers of Intramuscularly Administered Rabies Immune Globulin (Human)

Start: Mar 2014Est. completion: May 201412 patients
Phase 1Completed
NCT02241135CureVacCV7201 mRNA

RNActive® Rabies Vaccine (CV7201) in Healthy Adults

Start: Oct 2013Est. completion: Feb 2018101 patients
Phase 1Completed
NCT05382650GrifolsHuman rabies immune globulin 300 IU/mL

Survey of Human Rabies Immune Globulin Safety in Children

Start: Feb 2023Est. completion: Oct 202535 patients
N/ATerminated
NCT04213950GrifolsRabies PEP quality improvement bundle

Improving Adherence to Rabies PEP Guideline Recommendations

Start: Dec 2019Est. completion: Dec 202070 patients
N/ACompleted
NCT02729168Bharat BiotechHuman rabies vaccine

Safety Study of Rabies Vaccine INDIRAB® Five Doses (0.5ml) Post Exposure Administered Intramuscularly

Start: Oct 2015Est. completion: Dec 2015120 patients
N/ACompleted
NCT01063140CSL BehringRabies Vaccine

Rabies Immune Plasma Booster Study

Start: Jan 2009Est. completion: May 2010491 patients
N/ACompleted

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

6 late-stage (Phase 3) programs, potential near-term approvals
Vaccine is the dominant modality (93% of programs)
12 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.